CClinicalTrials.gg
CompletedNCT07526701Updated Apr 13, 2026

Clinical Application of Low-Field Magnetic Resonance Imaging in Patients on Extracorporeal Cardiopulmonary Resuscitation

An observational study in Cardiac Arrest (CA), Extracorporeal Cardiopulmonary Resuscitation and Acute Brain Injury, sponsored by Capital Medical University. Completed at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-04-13.

Sponsored by Capital Medical University · Observational

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
36
Ages
18 Years to 75 Years
Sex
All
01

Study summary

Timely identification of acute brain injury (ABI) patterns in patients with extracorporeal cardiopulmonary resuscitation (ECPR) is essential for prognostic assessment and optimization of clinical management, particularly anticoagulation strategies. This study aimed to evaluate the safety and feasibility of early 0.23-T MRI examination in ECPR patients. The investigators further assessed the image quality of the 0.23-T MRI and investigated the incidence and patterns of ABI, as well as their associations with neurological outcomes. This prospective observational study was conducted in the emergency intensive care unit (EICU) of Beijing Chaoyang Hospital, a high-volume ECPR center. The primary outcome was the feasibility of performing 0.23-T MRI in patients undergoing ECPR, defined as successful completion of the examination without serious adverse events (AEs).

02

Conditions studied

  • Cardiac Arrest (CA)
  • Extracorporeal Cardiopulmonary Resuscitation
  • Acute Brain Injury

Keywords

  • Cardiac Arrest
  • Extracorporeal Cardiopulmonary Resuscitation
  • Acute brain injury
  • Magnetic Resonance Imaging
03

In context

Heart Arrest

966 studies on the registry are indexed under Heart Arrest; 227 are open to participants now.

This study's enrollment of 36 is below the median of 200 across 383 observational studies indexed under Heart Arrest.

Browse Heart Arrest studies →

Lead sponsor

Capital Medical University is the lead sponsor of 283 studies on the registry; 92 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

Enrolled patients were those with out-of-hospital cardiac arrest of presumed cardiac cause, supported by ECPR, who achieved ROSC but remained unconscious and unable to obey verbal commands.

Inclusion criteria

  • Enrolled patients were those with out-of-hospital cardiac arrest of presumed cardiac cause, supported by ECPR, who achieved ROSC but remained unconscious and unable to obey verbal commands.

Exclusion criteria

Exclusion Criteria:

  • age \< 18 years
  • unwitnessed cardiac arrest
  • pregnancy
  • contraindications to MRI (except ECPR, for which safety with 0.23-T MRI has been proved)
  • physical dimensions exceeding scanner limits
  • refusal of consent by the family
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
36 participants (actual)
Target follow-up
1 Year
Patient registry
Yes

Groups and cohorts

  • Enrolled patients were those with out-of-hospital cardiac arrest of presumed cardiac cause
06

What researchers measure

Primary outcomes

  1. Feasibility of 0.23-T MRI examination

    Defined as the percentage of participants who successfully complete the MRI examination without experiencing serious adverse events (AEs). AEs include a decrease in ECMO flow \> 10%, a change in mean arterial pressure of ± 20%, or a change in minute ventilation \> 20%.

    Time frame: From the initiation of the MRI scan until 6 hours after its completion.

Secondary outcomes

  1. Image Quality

    Assessment of the diagnostic quality of 0.23-T MRI images by board-certified neuroradiologists to evaluate noise, artifacts, and anatomical clarity.

    Time frame: Within 6 hours after the completion of the MRI scan.

  2. Incidence of Acute Brain Injury (ABI)

    The proportion of patients identified with ABI patterns (such as ischemic stroke, intracranial hemorrhage, or cerebral edema) based on 0.23-T MRI findings.

    Time frame: From the onset of cardiac arrest to the completion of the MRI scan

  3. The association between ABI and neurological outcomes

    Neurological outcomes were assessed at 3 months after ROSC using the Glasgow-Pittsburgh Cerebral Performance Category (CPC) scale. The CPC scale ranges from 1 to 5, with 1 indicating good performance, 2 indicating moderate disability, 3 indicating severe disability, 4 indicating vegetative state and 5 indicating brain death or death. The neurological outcomes were categorized as favorable prognosis (CPC 1-2) and poor prognosis (CPC 3-5).

    Time frame: 3 months after ROSC.

07

Study locations

1 site
  • Department of Emergency Medicine, Beijing Chaoyang Hospital, Capital Medical University
    Beijing, Beijing Municipality 100020, China
08

References and documents

Publications

  • Suo Y, Du W, Xie X, Jiang Q, Zhang Z, Xu Y, Wei N, Zhu W, Qi N, Wang N, Xue B, Wang Y, Jiang Y, Meng X, Li Z, Zhao X, Li H, Wang Y, Jing J. Detecting acute ischemic lesions using mobile, low-field MRI in TIA and minor stroke in the emergency room. Int J Stroke. 2026 Apr;21(4):475-484. doi: 10.1177/17474930251378850. Epub 2025 Sep 4. PubMed 40905643 ↗

Individual participant data

Plan to share: No — Data supporting the findings of this study could be obtained from the corresponding author upon reasonable request.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Apr 13, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07526701
Lead sponsor
Capital Medical University
Responsible party
Tang Ziren (professor, Capital Medical University) — Principal investigator
First posted
Apr 13, 2026
Start date
Nov 1, 2024
Primary completion
Jan 1, 2026
Completion
Jan 1, 2026
Last update
Apr 13, 2026

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion